Angiopoietin 2/Ang-2/ANGPT2 Lentiviral Activation Particles (h): sc-400477-LAC

Human ANGPT2 encodes angiopoietin-2 (Ang-2), a secreted ligand of the endothelial receptor tyrosine kinase TIE2 (TEK) that regulates vascular remodeling and endothelial homeostasis. In concert with ANGPT1, Ang-2 modulates TIE2 phosphorylation to influence endothelial junction stability, pericyte interactions, and sprouting angiogenesis, integrating with VEGF-driven programs during inflammation and tissue remodeling. ANGPT2 expression is inducible by hypoxia, cytokines, and shear stress and is linked to endothelial activation, leukocyte trafficking, and increased vascular permeability. Dysregulated ANGPT2 signaling is associated with pathological angiogenesis and vascular dysfunction observed in cancer biology, retinopathies, sepsis-associated endotheliopathy, and chronic inflammatory diseases.

Angiopoietin 2/Ang-2/ANGPT2 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient ANGPT2 upregulation across a broader range of human cell types.

Angiopoietin 2/Ang-2/ANGPT2 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the ANGPT2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Angiopoietin 2/Ang-2/ANGPT2 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native ANGPT2 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.